Investigation of aqueous stability of taxol in different release media

References

• Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325–7
   PubMed Web of Science ®Google Scholar
• Safavy A, Raisch KP, Khazaeli MB, et al. Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes. J Med Chem 1999;42:4919–24
   PubMed Web of Science ®Google Scholar
• Pazdur R, Kudelka AP, Kavanagh JK, et al. The taxoids: paclitaxel (taxol) and docetaxel (taxotere). Cancer Treat Rev 1993;19:351–86
   PubMed Web of Science ®Google Scholar
• Li J, Strobel G, Sidhu R, et al. Endophytic taxol-producing fungi from bald cypress – Taxodium distichum. Microbiology 1996;142:2223–6
   PubMed Web of Science ®Google Scholar
• Fang GF, Chang BS, Kim CN, et al. “Loop” domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. Cancer Res 1998;58:3202–8
   PubMed Web of Science ®Google Scholar
• Rodi DJ, Janes RW, Sanganee HJ, et al. Screening of a library of phage-displayed peptides identifies human Bcl-2 as a taxolbinding protein. J Mol Biol 1999;285:197–203
   PubMed Web of Science ®Google Scholar
• Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 1979;227:665–7
   Web of Science ®Google Scholar
• Manfredi JJ, Horwitz SB. Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Therapeut 1984;25:83–125
   PubMed Web of Science ®Google Scholar
• Wenz F, Greiner S, Germa F, et al. Radiochemotherapy with paclitaxel: synchronization effects and the role of p53. Strahlenther Onkol 1999;175:2–6
   PubMed Web of Science ®Google Scholar
• Supiot S, Gouard S, Charrier J, et al. Mechanisms of cell sensitization to α radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines. Clin Cancer Res 2005;11:7047s–52s
   PubMed Web of Science ®Google Scholar
• Tiwari SB, Amiji MM. Improved oral delivery of paclitaxel following administration in nanoemulsion formulations. J Nanosci Nanotechnol 2006;6:3215–21
   PubMed Web of Science ®Google Scholar
• Ganta S, Amiji M. Co administration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharmacol 2009;6:928–39
   PubMed Web of Science ®Google Scholar
• Lo JT, Chen BH, Lee TM, et al. Self-emulsifying O/W formulations of paclitaxel prepared from mixed nonionic surfactants. J Pharm Sci 2010;99:2320–32
   PubMed Web of Science ®Google Scholar
• Alkan-Onyuksel H, Ramakrishnan S, Chai HB, Pezzuto JM. A mixed micellar formulation suitable for the parenteral administration of taxol. Pharmacol Res 1994;11:206–12
   Google Scholar
• Campbell RB, Balasubramanian SV, Straubinger RM. Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes. J Pharm Sci 2001;90:1091–105
   PubMed Web of Science ®Google Scholar
• Yang T, Choi M-K, Cui F-D, et al. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release 2007;120:169–77
   PubMed Web of Science ®Google Scholar
• Cho YW, Lee J, Lee SC, et al. Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles. J Control Release 2004;97:249–57
   PubMed Web of Science ®Google Scholar
• Huh KM, Min HS, Lee SC, et al. A new hydrotropic block copolymer micelle system for aqueous solubilization of paclitaxel. J Control Release 2008;126:122–9
   PubMed Web of Science ®Google Scholar
• Liang H, Yang Q, Deng L, et al. Phospholipid-Tween 80 mixed micelles as an intravenous delivery carrier for paclitaxel. Drug Dev Ind Pharm 2011;37:597–605
   PubMed Web of Science ®Google Scholar
• Nsereko S, Amiji M. Localized delivery of paclitaxel in solid tumors from biodegradable chitin microparticle formulations. Biomaterials 2002;23:2723–31
   PubMed Web of Science ®Google Scholar
• Hamoudeh M, Diab R, Fessi H, et al. Paclitaxel-loaded microparticles for intratumoral administration via the TMT technique: preparation, characterization, and preliminary antitumoral evaluation. Drug Dev Ind Pharm 2008;34:698–707
   PubMed Web of Science ®Google Scholar
• Burt HM, Jackson JK, Sarvjeet BK, et al. Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly(d,l-lactic acid). Cancer Lett 1995;88:73–9
   PubMed Web of Science ®Google Scholar
• Liggins RT, Burt HM. Paclitaxel loaded poly(l-lactic acid) microspheres: properties of microspheres made with low molecular weight polymers. Int J Pharm 2001;222:19–33
   PubMed Web of Science ®Google Scholar
• Li KW, Dang W, Tyler BM, et al. Polilactofate microspheres for paclitaxel delivery to central nervous system malignancies. Clin Cancer Res 2003;9:3441–7
   PubMed Web of Science ®Google Scholar
• Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038–44
   PubMed Web of Science ®Google Scholar
• Lim HJ, Nam HY, Lee BH, et al. A novel technique for loading of paclitaxel-PLGA nanoparticles onto ePTFE vascular grafts. Biotechnol Progr 2007;23:693–7
   PubMed Web of Science ®Google Scholar
• Yang R, Yang SG, Shim WS, et al. Lung-specific delivery of Paclitaxel by chitosan-modified PLGA nanoparticles via transient formation of microaggregates. J Pharm Sci 2009;98:970–84
   PubMed Web of Science ®Google Scholar
• Wu L, Tang C, Yin C. Folate-mediated solid--liquid lipid nanoparticles for paclitaxel-coated poly(ethylene glycol). Drug Dev Ind Pharm 2010;36:439–48
   PubMed Web of Science ®Google Scholar
• Kollipara S, Bende G, Movva S, Saha R. Application of rotatable central composite design in the preparation and optimization of poly(lactic-co-glycolic acid) nanoparticles for controlled delivery of paclitaxel. Drug Dev Ind Pharm 2010;36:1377–87
   PubMed Web of Science ®Google Scholar
• Wang Y, Jiang G, Qiu T, Ding F. Preparation and evaluation of paclitaxel-loaded nanoparticle incorporated with galactose-carrying polymer for hepatocyte targeted delivery. Drug Dev Ind Pharm 2012;38:1039–46
   PubMed Web of Science ®Google Scholar
• Yegin BA, Benoît J-P, Lamprecht A. Paclitaxel-loaded lipid nanoparticles prepared by solvent injection or ultrasound emulsification. Drug Dev Ind Pharm 2006;32:1089–94
   PubMed Web of Science ®Google Scholar
• Bartoli HM, Boitard M, Fessi H, et al. In vitro and in vivo antitumoral activity of free and encapsulated taxol. J Microencapsul 1990;7:191–7
   PubMed Web of Science ®Google Scholar
• Suh H, Jeong B, Rathi R, Kim SW. Regulation of smooth muscle cell proliferation using Paclitaxel-loaded poly(ethylene oxide)-poly(lactide/glycolide) nanospheres. J Biomed Mater Res 1998;42:331–8
   PubMed Web of Science ®Google Scholar
• Khandavilli S, Panchagnula R. Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats. J Invest Dermatol 2007;127:154–62
   PubMed Web of Science ®Google Scholar
• Hosmer JM, Shin SH, Nornoo A, et al. Influence of internal structure and composition of liquid crystalline phases on topical delivery of paclitaxel. J Pharm Sci 2011;100:1444–55
   PubMed Web of Science ®Google Scholar
• Finkelstein A, McClean D, Kar S, et al. Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation 2003;107:777–84
   PubMed Web of Science ®Google Scholar
• Alexis F, Venkatraman SS, Rath SK, Boey F. In vitro study of release mechanisms of paclitaxel and rapamycin from drug-incorporated biodegradable stent matrices. J Control Release 2004;98:67–74
   PubMed Web of Science ®Google Scholar
• Shin YM, Lim KS, Jin JY, et al. In vitro and in vivo characterization of a coronary stent coated with an elastic biodegradable polymer for the sustained release of paclitaxel. Macromol Res 2009;17:1039–42
   Web of Science ®Google Scholar
• Bege N, Steinmüller SO, Kalinowskic M, et al. Drug eluting stents based on poly(ethylene carbonate): optimization of the stent coating process. Eur J Pharm Biopharm 2012;80:562--70
   PubMed Web of Science ®Google Scholar
• Tailor J, Raval A, Engineer C, et al. Development and validation of a reversed-phase HPLC method for in-vitro loading and release analysis of paclitaxel coated stent. Trends Biomater Artif Organs 2008;22:79–86
   Google Scholar
• Washington C. Drug release from microdisperse systems: a critical review. Int J Pharm 1990;58:1–12
   Web of Science ®Google Scholar
• Dordunoo SK, Jackson JK, Arsenault LA, et al. Taxol encapsulation in poly(ε-caprolactone) microspheres. Cancer Chemoth Pharm 1995;36:279–82
   PubMed Web of Science ®Google Scholar
• Springate CM, Jackson JK, Gleave ME, Burt HM. Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models. Cancer Chemoth Pharm 2005;56:239–47
   PubMed Web of Science ®Google Scholar
• Song D, Hsu LF, Au JL. Binding of taxol to plastic and glass containers and protein under in vitro conditions. J Pharm Sci 1996;85:29–31
   PubMed Web of Science ®Google Scholar
• Montaseri H, Jamali F, Rogers JA, et al. The effect of temperature, pH, and different solubilizing agents on stability of taxol. Iran J Pharm Sci 2004;1:43–51
   Google Scholar
• Hamada H, Ishihara K, Masuoka N, et al. Enhancement of water-solubility and bioactivity of paclitaxel using modified cyclodextrins. J Biosci Bioeng 2006;102:369–71
   PubMed Web of Science ®Google Scholar
• Winternitz CI, Jackson JK, Oktaba AM, Burt HM. Development of a polymeric surgical paste formulation for taxol. Pharmacol Res 1996;13:368–75
   Google Scholar
• Lee SC, Huh KM, Lee J, et al. Hydrotropic polymeric micelles for enhanced paclitaxel solubility: in vitro and in vivo characterization. Biomacromolecules 2007;8:202–8
   PubMed Web of Science ®Google Scholar
• Baek N, Lee J, Park J. Aqueous N,N-diethylnicotinamide (DENA) solution as a medium for accelerated release study of Paclitaxel. J Biomater Sci Polym Ed 2004;15:527–42
   PubMed Web of Science ®Google Scholar
• Harper E, Dang W, Lapidus RG, Jr. Garver RI. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice. Clin Cancer Res 1999;5:4242–8
   PubMed Web of Science ®Google Scholar
• Jackson JK, Skinner KC, Burgess L, et al. Paclitaxel-loaded crosslinked hyaluronic acid films for the prevention of postsurgical adhesions. Pharm Res 2002;19:411–17
   PubMed Web of Science ®Google Scholar
• Ringel I, Horwitz SB. Taxol is converted to 7-epitaxol, a biologically active isomer, in cell culture medium. J Pharmacol Exp Ther 1987;242:692–8
   PubMed Web of Science ®Google Scholar
• Nguyen T, Eshraghi J, Gonyea G, et al. Studies on factors influencing stability and recovery of paclitaxel from suspension media and cultures of Taxus cuspidata cv Densiformis by high-performance liquid chromatography. J Chromatogr A 2001;911:55–61
   PubMed Web of Science ®Google Scholar
• Tian J, Stella VJ. Degradation of paclitaxel and related compounds in aqueous solutions I: epimerization. J Pharm Sci 2008;97:1224–35
   PubMed Web of Science ®Google Scholar
• Samaranayake G, Magri NF, Jitrangsri C, Kingston DGI. Modified taxols. 5. Reaction of taxol with electrophilic reagents and preparation of a rearranged taxol derivative with tubulin assembly activity. J Org Chem 1991;56:5114–19
   Web of Science ®Google Scholar
• Tian J, Stella VJ. Degradation of paclitaxel and related compounds in aqueous solutions II: nonepimerization degradation under neutral to basic pH conditions. J Pharm Sci 2008;97:3100–8
   PubMed Web of Science ®Google Scholar
• Tian J, Stella VJ. Degradation of paclitaxel and related compounds in aqueous solutions III: degradation under acidic pH conditions and overall kinetics. J Pharm Sci 2010;99:1288–98
   PubMed Web of Science ®Google Scholar
• Lee J, Lee SC, Acharya G, et al. Hydrotropic solubilization of paclitaxel: analysis of chemical structures for hydrotropic property. Pharm Res 2003;20:1022–30
   PubMed Web of Science ®Google Scholar
• Huang CHO, Kingston DGI, Magri NF, et al. New taxanes from Taxus brevifolia, 2. J Nat Prod 1986;49:665–9
   PubMed Web of Science ®Google Scholar
• Castellano EE, Hodder OJR. Crystal and molecular structure of the diterpenoid baccatin V, a naturally occurring oxetane with a taxane skeleton. Acta Crystallogr Sect B: Struct Crystallogr Cryst Chem 1973;29:2566–70
   Web of Science ®Google Scholar
• Miller RW, Powell RG, Smith Jr CR, et al. Antileukemic alkaloids from Taxus wallichiana Zucc. J Org Chem 1981;46:1469–73
   Web of Science ®Google Scholar
• Williams HJ, Scott AL, Dieden RA, et al. NMR and molecular modeling study of the conformations of taxol and its side chain methyl ester in aqueous and nonaqueous solution. Tetrahedron 1993;49:6545–60
   Web of Science ®Google Scholar
• McLaughlin JL, Miller RW, Powell RG, SmithJr CR. 19-Hydroxybaccatin III, 10-deacetylcephalomannine, and 10-deacetyltaxol: New antitumor taxanes from Taxus wallichiana. J Nat Prod 1981;44:312–19
   PubMed Web of Science ®Google Scholar
• MacEachern-Keith GJ, Butterfield LJ, Mattina IMJ. Paclitaxel stability in solution. Anal Chem 1997;69:72–7
   Web of Science ®Google Scholar
• Dordunoo SK, Burt HM. Solubility and stability of taxol: effects of buffers and cyclodextrins. Int J Pharm 1996;133:191–201
   Web of Science ®Google Scholar
• Richheimer SL, Tinnermeier DM, Timmons DW. High-performance liquid chromatographic assay of taxol. Anal Chem 1992;64:2323–6
   PubMed Web of Science ®Google Scholar
• Kuh H-J, Jang SH, Wientjes MG, et al. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther 1999;290:871–80
   PubMed Web of Science ®Google Scholar